Phase II Study of JS207 Alone or With JS004 or Docetaxel for Advanced Non-small Cell Lung Cancer After Platinum-based Chemotherapy and Immunotherapy

What this Trial Is About

Researchers are evaluating the safety, tolerability, and early effects of JS207 in adults with advanced non-small cell lung cancer NSCLC who have experienced disease progression after receiving platinum-based chemotherapy and immunotherapy. This phase II trial aims to assess how well JS207 works alone or combined with other treatments in this setting. Participants receive one of three treatments JS207 with docetaxel chemotherapy every three weeks, JS207 with JS004 antibody every three weeks, or JS207 alone at 10mgkg or another dose. These groups allow comparison of different combinations to explore potential benefits and safety profiles. During the study, participants will be monitored for tumor response, disease control, duration of response, progression-free survival, overall survival, and any adverse effects or laboratory abnormalities. These outcomes will be assessed over periods ranging from 1.5 to 2 years to gather comprehensive information about treatment effects and safety.

Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy